

## Lumito publishes equity research report on Lumito

**As announced by Lumito AB (publ) (“Lumito” or the “Company”) on January 13, 2026, Analyst Group conducts equity research coverage of Lumito, commissioned by the Company. The coverage includes equity research with quarterly updates as well as analyst comments on reports and press releases. Today, Analyst Group has published its first report on the Company.**

Today, March 10, 2026, Analyst Group published an equity report on Lumito, which is available on Analyst Group’s website at the following link: <https://analystgroup.se/analyser/lumito/>. The report has been commissioned and paid for by the Company.

### For further information, please contact:

---

Sanna Wallenborg, CEO Lumito

E-mail: [sw@lumito.se](mailto:sw@lumito.se)

Ph: +4670-870 01 68

### About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. [www.lumito.se/en/](http://www.lumito.se/en/)

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

### Attachments

[Lumito publishes equity research report on Lumito](#)